89830-98-8

Basic information

• Product Name: 4-Cyclopropyl-1(3)H-iMidazole
• Synonyms: 4-Cyclopropyl-1(3)H-iMidazole;5-Cyclopropyl-1H-iMidazole;4-cyclopropyl-1H-imidazole
• CAS NO: 89830-98-8
• Molecular Formula: C₆H₈N₂
• Molecular Weight: 108.14112
• EINECS: -0
• Mol File: 89830-98-8.mol

Chemical Properties

• Boiling Point: 313.5±11.0 °C(Predicted)
• Appearance: /
• Density: 1 +-.0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 14.84±0.10(Predicted)
• CAS DataBase Reference: 4-Cyclopropyl-1(3)H-iMidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Cyclopropyl-1(3)H-iMidazole(89830-98-8)
• EPA Substance Registry System: 4-Cyclopropyl-1(3)H-iMidazole(89830-98-8)

Safety Data

• Hazardous Substances Data: 89830-98-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
4-Cyclopropyl-1(3)H-imidazole serves as a valuable building block in the pharmaceutical industry. It is utilized as a key intermediate in the synthesis of various drugs, contributing to the development of new therapeutic agents. Its unique cyclopropyl-imidazole structure allows for the creation of molecules with specific biological activities, making it an essential component in medicinal chemistry.
Used in Agrochemical Production:
In the agrochemical sector, 4-Cyclopropyl-1(3)H-imidazole is employed as a starting material for the synthesis of various agrochemicals. Its incorporation into these compounds can enhance their effectiveness in pest control and crop protection, thereby contributing to increased agricultural productivity.
Used in Heterocyclic Compound Synthesis:
4-Cyclopropyl-1(3)H-imidazole is also used as a starting material in the production of other heterocyclic compounds. Its unique structure allows for the formation of diverse heterocyclic systems, which are important in various chemical and biological applications, including the development of new materials and pharmaceuticals.
Overall, the unique structure and properties of 4-Cyclopropyl-1(3)H-imidazole make it a versatile and valuable molecule in the fields of organic chemistry, pharmaceuticals, and agrochemicals. Its applications in these industries highlight its importance in the development of new and effective compounds for various purposes.

Upstream product

• 69267-75-0 2-bromo-1-cyclopropylethan-1-one 
• 3473-63-0 formamidine acetic acid 
• 765-43-5 Cyclopropyl methyl ketone 
• 81447-28-1 2-cyclopropyl-2-oxoethyl 4-methylbenzenesulfonate 
• 463-52-5 formamidine 
• 773837-37-9 sodium cyanide 
• 38622-91-2 [(p-methylphenyl)sulfonylmethyl]isonitrile 
• 1489-69-6 Cyclopropanecarboxaldehyde 

Downstream Products

• 1240347-32-3 3-(4-cyclopropyl-1H-imidazol-1-yl)-5-(trifluoromethyl)aniline 
• 1354412-91-1 isopropyl 5-(4-cyclopropyl-1H-imidazol-1-yl)-2-methoxy-benzoate 
• 1434584-96-9 C₁₈H₁₇N₇O 
• 1448428-03-2 5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methylbenzoic acid hydrochloride 
• 1448428-04-3 5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methyl-N-{6-[4-(propan-2-yl)-4H-1,2,4-triazol-3-yl]pyridin-2-yl}benzamide 
• 1448508-47-1 5-(4-cyclopropyl-1H-imidazole-1-yl)-2-fluoro-4-methylbenzoic acid 

Relevant articles and documents

NOVEL APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS

The present invention relates to inhibitors of apoptosis signal-regulating kinase 1 ("ASK1"), a process for synthesis of the compounds of the present invention, composition comprising the compounds and use of the compounds for inhibition of ASK1.

ASK1 inhibitor and application thereof

The invention relates to compounds represented by a general formula (I) shown in the specification, a pharmaceutically acceptable salt and ester, or a stereoisomer of the compounds. The invention alsorelates to a preparation method of the compounds, a pharmaceutical preparation and a pharmaceutical composition containing the compounds. The compounds provided by the invention can effectively inhibit the amino acid phosphorylation of ASK1 and inhibit the activation of the ASK1; therefore, the compounds can treat and/or prevent ASK1-mediated diseases and related diseases.

Substituted triazole compound, pharmaceutical composition containing substituted triazole compound, preparation method and application of substituted triazole compound

The present invention relates to a substituted triazole compound represented by formula (I), a pharmaceutical compositions comprising the substituted triazole compound, a preparation method of the substituted triazole compound, and applications of the sub

ASK1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF

The present disclosure relates to a compound as shown in formula (II), a tautomer or a pharmaceutically acceptable salt thereof, and disclosed is the use thereof in preparing a drug for treating an ASK1-associated disease.

Novel ASK1 inhibitor and application thereof

The invention relates to a compound shown as a general formula (I), a pharmacologically acceptable salt, ester or a stereisomer. The invention also relates to a preparation method of the compound, a medicine preparation containing the compound and a medic

PYRIDINYL BASED APOPTOSIS SIGNAL-REGULATION KINASE INHIBITORS

Apoptosis signal-regulating kinase 1 (ASK1) activation and signaling have been reported to play an important role in a broad range of diseases including neurodegenerative, cardiovascular, inflammatory, autoimmunity and metabolic disorders. Disclosed herein is the synthesis of pyridinyl derived therapeutic agents that function as inhibitors of ASK 1 as well as their pharmaceutical compositions and methods of use.

PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS

The present invention relates to purine derivatives of formula (I), processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.

APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS

The present invention relates to compounds of Formula (I): where in X1, X2, X3, X4, X5, X6, X7, X8, R1, R2, R3 are as defined above. T

DISUBSTITUTED IMIDAZOLE DERIVATIVES AS MODULATORS OF RAF KINASE

Novel substituted imidazole compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with an additional agent f

AMIDES AS KINASE INHIBITORS

The present invention is directed to amides, and pharmaceutical compositions thereof, which are inhibitors of kinases such as BCR AbI, FLT3, c-Kit, KDR, LCK, Epha2 and PDGFR subfamily and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.